Biogen · 1 day ago
Intern, Clinical Development
Cambridge, MA
Internship
Hybrid
InternBiogen is a mid-sized biotechnology company committed to delivering life-changing medicines. The Clinical Development Group seeks a talented intern to gather and analyze data to support clinical trial outcomes, focusing on immunology and neurology diseases.
BiotechnologyHealth CareNeuroscienceTherapeutics
Responsibilities
Gathering and analyzing data to support efforts to better understand clinical trial outcomes
Work collaboratively with team members and groups across Biogen
Identify data sources, gathering data, and conducting analyses to support disease-specific clinical trials
Explore elements of the patient journey in an effort to better understand the scientific basis for responses to therapies
Qualification
Required
Legal authorization to work in the U.S
Grade point average of 3.2 or higher preferred
At least 18 years of age prior to the scheduled start date
Be currently enrolled in an accredited college or university
Degree-seeking college coursework in a scientific field required
Experience in biological understanding of human disease, especially neuroscience or immunology
Interest in clinical trials
Familiarity with analysis and interpretation of experimental results
Benefits
Company paid holidays
Commuter benefits
Employee Resource Groups participation
80 hours of sick time per calendar year
Company
Biogen
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Founded in 1978Cambridge, Massachusetts, USA
5001-10000 employees
H1B Sponsorship
Biogen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (100)
2024 (93)
2023 (101)
2022 (134)
2021 (104)
2020 (114)
Funding
Current Stage
Public CompanyTotal Funding
$1.5BKey Investors
JP Morgan
2023-08-28Post Ipo Debt· $1.5B
1991-09-27IPO
Leadership Team
Robin C. Kramer
Executive Vice President, Chief Financial Officer
Priya Singhal
Executive Vice President, Head of Development
Recent News
2026-01-16
2026-01-16
Company data provided by crunchbase